Get started
Author

Christoph Tapprich

Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings
2005 · F Neumann, T Graef, et al. · Bone Marrow Transplantation · 82
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes
2008 · Michael Wulfert, Anna C. Küpper, et al. · Experimental Hematology · 58
Burden of illness of follicular lymphoma and marginal zone lymphoma
2018 · Neerav Monga, Loretta Nastoupil, et al. · Annals of Hematology · 32
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial
2017 · Hermann Einsele, Monika Engelhardt, et al. · British Journal of Haematology · 32
Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma
2003 · C Tapprich, R Fenk, et al. · Bone Marrow Transplantation · 26
Systematic literature review of the global burden of illness of mantle cell lymphoma
2020 · Neerav Monga, Jamie Garside, et al. · Current Medical Research and Opinion · 17
FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
2022 · Caroline Dartigeas, Borhane Slama, et al. · Clinical Hematology International · 15
PDF
Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review
2020 · Neerav Monga, Constantine Tam, et al. · Critical Reviews in Oncology/Hematology · 15
Optimized PCR fragments for heteroduplex analysis of the whole human mitochondrial genome with denaturing HPLC
2006 · Michael Wulfert, Christoph Tapprich, et al. · Journal of Chromatography B · 15
Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML)
2015 · Jörg Tomeczkowski, Ansgar Lange, et al. · Advances in Therapy · 10
PDF
Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews
2020 · Neerav Monga, Jamie Garside, et al. · PharmacoEconomics - Open · 9
PDF
Bortezomib-Containing Regimens Are Effective in Multiple Myeloma - Results of a Non-Interventional Phase IV Study
2015 · Wolfgang Knauf, Christoph Tapprich, et al. · Oncology Research and Treatment · 7
Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma
2020 · Neerav Monga, Jamie Garside, et al. · PharmacoEconomics - Open · 6
PDF
Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review
2020 · Marcell Csanádi, Tamas Ágh, et al. · Expert Review of Hematology · 6
Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review
2022 · Marcell Csanádi, Tamás Ágh, et al. · Expert Review of Hematology · 4
Prevalence and Treatment of Chronic Lymphocytic Leukaemia (Cll) In Germany: An Analysis of Sickness Funds
2014 · J. Tomeczkowski, M.K. Leisten, et al. · Value in Health · 4
Cyclosporine A and Mycophenolate Mofetil Versus Cyclosporine A and Methotrexate for Graft Versus Host Disease Prophylaxis after Stem Cell Transplantation from HLA-Identical Siblings.
2004 · Frank Neumann, Thorsten Graef, et al. · Blood · 3
Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting
2022 · Jose Angel Hernandez-Rivas, Pier Luigi Zinzani, et al. · Blood · 2
Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database
2018 · Lionel Karlin, Hervé Besson, et al. · Blood · 2
Review Of Real-World Evidence To Assess The Burden Of Illness Of Mantle Cell Lymphoma
2017 · N Monga, J Garside, et al. · Value in Health · 2
Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies
2025 · Catherine Thieblemont, Emmanuelle Tchernonog, et al. · Blood
PDF
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort
2025 · Talha Munir, Danielle Leão, et al. · Future Oncology
PDF
Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review
2020 · Csanádi, Marcell, Ágh, Tamas, et al. · Figshare
Pcn479 Patient-reported Symptom Burden of Chronic Graft Versus Host Disease: a Systematic Literature Review
2019 · M. Csanádi, S. Farkas, et al. · Value in Health
Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma
2018 · Neerav Monga, Jamie Garside, et al. · Blood
Works count: 38
Citation count: 347
H-index: 10
I10-index: 10
Year
Topic
Type